Results 231 to 240 of about 149,982 (306)

Unveiling the Uncommon: Pyoderma Gangrenosum as an Extraintestinal Complication of Ulcerative Colitis. [PDF]

ACG Case Rep J
Glover C, Rida A, Nguyen E, Cay E, Ocasio-Cortes G, Stefanko S, Fotouhi A, Ross A.   +7 more
europepmc   +1 more source

The Understudied Landscape of Hidradenitis Suppurativa in Asian Skin of Colour Populations

JEADV Clinical Practice, EarlyView.
Anju George
wiley   +1 more source

Epidemiology and the cost burden of hospitalized pediatric‐onset inflammatory bowel disease in China: A national database study

Pediatric Investigation, EarlyView.
This study provides insights into the clinical characteristics and cost burden of pediatric‐onset inflammatory bowel disease (PIBD) and very early onset IBD (VEO‐IBD) in China. Hospitalizations for PIBD, particularly Crohn's disease, are increasing. Guidelines and health insurance policies can help mitigate the cost burden.
Xiaolu Nie, Jing Li, Hui Xu, Fang Hu, Xiaolin Ye, Mengmeng Yu, Guoshuang Feng, Yueping Zeng, Xin Ni, Jie Wu, Xiaoxia Peng, the Futang Research Center of Pediatric Development (FRCPD)   +11 more
wiley   +1 more source

Association between Dietary Inflammatory Index and Ulcerative Colitis: a case-control study. [PDF]

BMC Gastroenterol
Pan H, Zhai L, Cui M, Liu Y, Shao L, Liu L, Yao P.   +6 more
europepmc   +1 more source

Characteristics, properties and limitations of per‐ or polyfluoroalkyl substances (PFASs) and fluoropolymers

Polymer International, EarlyView.
An overview and categorization of man‐made per‐ or polyfluoroalkyl substances (PFASs) including low‐molar‐mass and high‐molar‐mass fluorochemicals, and their international regulations is presented. Though certain PFASs are toxic, bioaccumulative and cross the human cellular membranes, others, such as fluoropolymers, are safe, reliable and involved in ...
Bruno Améduri
wiley   +1 more source

In which patients with ulcerative colitis would filgotinib be effective? [PDF]

Intest Res
Park J.
europepmc   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

Unraveling the complexity of ulcerative colitis: insights into cytokine dysregulation and targeted therapies. [PDF]

EXCLI J
Shimomori Y, Yokoyama Y, Kurumi H, Akita K, Kazama T, Hayashi Y, Mizukami K, Nakase H.   +7 more
europepmc   +1 more source

Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Rocatinlimab (AMG 451/KHK4083) is a potential T‐cell rebalancing therapy that inhibits and reduces the number of pathogenic T cells by targeting the OX40 receptor; it is associated with a progressive and sustained response for patients with moderate‐to‐severe atopic dermatitis (AD).
Hiroki Okada, Sam Liao, Lisa Khouri, Lori Liao, Matthew W. Hruska, Yoshinori Nagata, Maki Hasegawa, Andrew Gewitz, Douglas Marsteller   +8 more
wiley   +1 more source

Dietary inflammatory potential, genetic predisposition, and incidence of Crohn's disease and ulcerative colitis. [PDF]

Nutr Metab (Lond)
Gu JM, Zhao M, Zhu J, Tao HW, Shao XP, Qin LQ, Ge YY, Chen GC.   +7 more
europepmc   +1 more source